Company Overview and News

to your dashboard

Headline News

Ligand Pharmaceuticals' (LGND) Presents at Analyst Day (Transcript)

2017-11-15 seekingalpha
Welcome. Thank you, everyone, for joining us. Ligand's end-of-the-year Analyst Day 2018 and beyond. We appreciate the turnout. We got a nice group on the audience today. The attendees on the webcast that continue to add and we really do appreciate your attention here at the end of day and close to the end of the year. My name is John Higgins, I'm the CEO of Ligand. I'm joined by several of our colleagues. (115-0)

7 Life Science Stocks to Buy Today | InvestorPlace

2017-11-14 investorplace
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like? (236-1)

Sage Therapeutics' Positive Phase 3 Results Bring Hope To Childbearing Women

2017-11-13 seekingalpha
The company may need to raise cash in the coming months in order to continue operations. (19-0)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Investors Giving Thanks For Sage Therapeutics

2017-11-10 seekingalpha
Strong Bio first covered Sage Therapeutics on July 6, 2017, and below is a follow-up to that article. (19-0)

Sage Therapeutics Wins Big in Depression Trial

2017-11-09 247wallst
Sage Therapeutics Inc. (NASDAQ: SAGE) shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum depression (PPD). Ultimately the Phase 3 clinical trials of brexanolone (formerly SAGE-547) achieved the primary endpoints in each. (19-0)

Biotech Forum Daily Digest: Redhill's Bungled Secondary

2017-11-09 seekingalpha
The biotech sector continues to head down this week as sentiment on the high beta areas of the market weaken. (159-1)

UPDATE 3-Sage soars as postpartum depression drug moves closer to approval

2017-11-09 reuters
(Reuters) - Sage Therapeutics Inc’s shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder. (19-0)

Dow off 130 points, flirts with worst daily decline in 2 months - MarketWatch

2017-11-09 marketwatch
U.S. stocks opened firmly lower on Thursday as Wall Street awaited the Senate version of a GOP-led tax bill, with the investors appearing to wager that the prospects for passage of reforms to tax policy soon were low. The Dow Jones Industrial Average DJIA, -0.49% fell 132 points, or 0.6%, 23,432, threatening to fall the most since Sept. 5, the S&P 500 index SPX, -0.55% slipped 16 points, or 0.5% at 2,581, while the Nasdaq Composite Index COMP, -0. (19-0)

Sage Therapeutics stock bounces 44% after positive results for depression treatment - MarketWatch

2017-11-09 marketwatch
Positive postpartum depression results have investors looking to Sage’s major depressive disorder drug, with results expected this year (19-0)

Sage Therapeutics stock surges 50% on positive trial results in postpartum depression - MarketWatch

2017-11-09 marketwatch
Sage Therapeutics Inc. SAGE, -1.73% shares surged 50% in premarket trade Thursday after the company said its postpartum depression therapy has positive results in two late-stage clinical trials. The therapy, brexanolone, met the primary endpoint in both trials, was generally well-tolerated by patients and was similarly safe as in earlier trials, Sage said. One clinical trial enrolled patients with moderate postpartum depression, while the other enrolled those with severe postpartum depression; in both trials, patients on the therapy had a reduction in a score assessing their depression levels as compared with the placebo from 60 hours after taking the therapy to 30 days later. (19-0)

Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?

2017-11-07 seekingalpha
Portola Pharma is a $3.5b market cap biopharmaceutical company with annualized revenue of ~$100m and a cash burn rate of ~$200m. (43-3)

SAGE Therapeutics: Postpartum Depression Play

2017-11-06 seekingalpha
SAGE Therapeutics, Inc. (SAGE) is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of drugs treating central nervous system CNS disorders. On November 2nd, 2017 the company announced third quarter financial results and provided updates on its pipeline. I will cover some of the points in the data update, discuss recent failures, and suggest buying ahead of near term data readout catalysts. (19-0)

Marinus Pharmaceuticals: The Next Big Thing In CNS

2017-10-31 seekingalpha
Orphan drug designation, paired with unprecedented data, enables expedited approval of Ganaxolone in CDKL5 and additional orphan pediatric indications. (165-2)

CUSIP: 78667J108